SUWANEE, GA--(MARKET WIRE)--Aug 22, 2007 -- Oncologix Tech Inc. (OTC BB:OCLG.OB - News) announced today that it has qualified a new design of its Oncosphere product in response to the “leaching” problem found in its previous design and described in an earlier press release. The improved design was developed and qualified with the aid of its current team and a new collaborator, Starpharma’s subsidiary Dendritic Nanotechnologies, Inc. (DNT) located in Mount Pleasant, Michigan.
